The ARHGAP4 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-mediated gene disruption pool targeting the ARHGAP4 locus in the HAP1 near-haploid human cell line. This product consists of a polyclonal population of knockout cells, each carrying heterogeneous gene edits, which collectively provide a loss-of-function model for studying ARHGAP4-dependent cellular processes without the need for clonal isolation. The polyclonal format is particularly advantageous for capturing the diversity of editing outcomes and avoiding clonal artifacts, making it suitable for pooled screening approaches and robust functional genomics analyses.
HAP1 cells are a near-haploid human cell line derived from the KBM-7 chronic myeloid leukemia background. Their single-copy genome simplifies genetic loss-of-function studies by avoiding heterozygosity. Widely used in knockout screens and targeted gene editing, HAP1 cells offer stable growth and compatibility with standard culture conditions, making them an ideal host for investigating gene function in a clean genetic background.
ARHGAP4 encodes a Rho GTPase-activating protein that negatively regulates Rho family GTPases such as RhoA, Rac1, and Cdc42 by accelerating GTP hydrolysis. This function is critical for modulating actin cytoskeleton dynamics, cell adhesion, and migration. Upstream signals from receptor tyrosine kinases and cell?Cextracellular matrix interactions regulate ARHGAP4 activity, while it interacts with phosphoinositides and cytoskeletal adaptor proteins. Key downstream effectors influenced by this regulation include ROCK, mDia1, and the Arp2/3 complex, which drive actin polymerization and focal adhesion turnover. Consequently, ARHGAP4 integrates signals to control integrin-mediated adhesion and motility, with established roles in cancer progression, glioma invasion, and metastasis.
Loss of ARHGAP4 in HAP1 cells results in unopposed Rho GTPase signaling, leading to altered actin remodeling, adhesion, and cell migration. This haploid knockout model allows precise assessment of ARHGAP4-dependent phenotypes without allelic interference, and the polyclonal pool captures diverse editing outcomes for robust functional analyses. The model is particularly suited for exploring mechanisms of cancer cell invasiveness and testing anti-metastatic drug candidates.
Applications include functional genomics, Rho GTPase signaling pathway analysis, cancer cell migration and invasion assays (e.g., wound healing, transwell), drug target validation, and genetic interaction screens. Compatible techniques include western blotting for Rho GTPase levels, Rho activation assays (G-LISA), actin staining, proliferation assays, and RNA-seq transcription profiling. For further details or to discuss custom applications, please contact Ascent Research.
